These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 34937342)

  • 1. Abundance, Betweenness Centrality, Hydrophobicity, and Isoelectric Points Are Relevant Factors in the Processing of Parental Proteins of the HLA Class II Ligandome.
    Lorente E; Martín-Galiano AJ; Kadosh DM; Barriga A; García-Arriaza J; Mir C; Esteban M; Admon A; López D
    J Proteome Res; 2022 Jan; 21(1):164-171. PubMed ID: 34937342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomics Analysis Reveals That Structural Proteins of the Virion Core and Involved in Gene Expression Are the Main Source for HLA Class II Ligands in Vaccinia Virus-Infected Cells.
    Lorente E; Martín-Galiano AJ; Barnea E; Barriga A; Palomo C; García-Arriaza J; Mir C; Lauzurica P; Esteban M; Admon A; López D
    J Proteome Res; 2019 Mar; 18(3):900-911. PubMed ID: 30629447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acid Stripping after Infection Improves the Detection of Viral HLA Class I Natural Ligands Identified by Mass Spectrometry.
    Lorente E; Marcilla M; de la Sota PG; Quijada-Freire A; Mir C; López D
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sampling From the Proteome to the Human Leukocyte Antigen-DR (HLA-DR) Ligandome Proceeds Via High Specificity.
    Mommen GP; Marino F; Meiring HD; Poelen MC; van Gaans-van den Brink JA; Mohammed S; Heck AJ; van Els CA
    Mol Cell Proteomics; 2016 Apr; 15(4):1412-23. PubMed ID: 26764012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction.
    Abelin JG; Harjanto D; Malloy M; Suri P; Colson T; Goulding SP; Creech AL; Serrano LR; Nasir G; Nasrullah Y; McGann CD; Velez D; Ting YS; Poran A; Rothenberg DA; Chhangawala S; Rubinsteyn A; Hammerbacher J; Gaynor RB; Fritsch EF; Greshock J; Oslund RC; Barthelme D; Addona TA; Arieta CM; Rooney MS
    Immunity; 2019 Oct; 51(4):766-779.e17. PubMed ID: 31495665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ligandomes obtained from different HLA-class II-molecules are homologous for N- and C-terminal residues outside the peptide-binding cleft.
    Kampstra ASB; van Heemst J; Janssen GM; de Ru AH; van Lummel M; van Veelen PA; Toes REM
    Immunogenetics; 2019 Sep; 71(8-9):519-530. PubMed ID: 31520135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The HLA-DP peptide repertoire from human respiratory syncytial virus is focused on major structural proteins with the exception of the viral polymerase.
    Lorente E; Barnea E; Mir C; Admon A; López D
    J Proteomics; 2020 Jun; 221():103759. PubMed ID: 32244010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.
    Berlin C; Kowalewski DJ; Schuster H; Mirza N; Walz S; Handel M; Schmid-Horch B; Salih HR; Kanz L; Rammensee HG; Stevanović S; Stickel JS
    Leukemia; 2015 Mar; 29(3):647-59. PubMed ID: 25092142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The human leukocyte antigen-presented ligandome of B lymphocytes.
    Hassan C; Kester MG; de Ru AH; Hombrink P; Drijfhout JW; Nijveen H; Leunissen JA; Heemskerk MH; Falkenburg JH; van Veelen PA
    Mol Cell Proteomics; 2013 Jul; 12(7):1829-43. PubMed ID: 23481700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 proteins in infected cells determine the presentation of viral peptides by HLA class I and class II molecules and the nature of the cellular and humoral antiviral immune responses--a review.
    Becker Y
    Virus Genes; 1994 Jul; 8(3):249-70. PubMed ID: 7975271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Analysis of CD4
    Hyun YS; Jo HA; Lee YH; Kim SM; Baek IC; Sohn HJ; Cho HI; Kim TG
    Front Immunol; 2020; 11():602014. PubMed ID: 33658991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-DR and HLA-DP restricted epitopes from human cytomegalovirus glycoprotein B recognized by CD4+ T-cell clones from chronically infected individuals.
    Ventura C; Bisceglia H; Girerd-Chambaz Y; Burdin N; Chaux P
    J Clin Immunol; 2012 Dec; 32(6):1305-16. PubMed ID: 22797815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA class I binding 9mer peptides from influenza A virus induce CD4 T cell responses.
    Wang M; Larsen MV; Nielsen M; Harndahl M; Justesen S; Dziegiel MH; Buus S; Tang ST; Lund O; Claesson MH
    PLoS One; 2010 May; 5(5):e10533. PubMed ID: 20479886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).
    Kowalewski DJ; Schuster H; Backert L; Berlin C; Kahn S; Kanz L; Salih HR; Rammensee HG; Stevanovic S; Stickel JS
    Proc Natl Acad Sci U S A; 2015 Jan; 112(2):E166-75. PubMed ID: 25548167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma.
    Jäger E; Jäger D; Karbach J; Chen YT; Ritter G; Nagata Y; Gnjatic S; Stockert E; Arand M; Old LJ; Knuth A
    J Exp Med; 2000 Feb; 191(4):625-30. PubMed ID: 10684854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1.
    Krüger S; Schroers R; Rooney CM; Gahn B; Chen SY
    J Immunother; 2003; 26(3):212-21. PubMed ID: 12806275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas.
    Dengjel J; Nastke MD; Gouttefangeas C; Gitsioudis G; Schoor O; Altenberend F; Müller M; Krämer B; Missiou A; Sauter M; Hennenlotter J; Wernet D; Stenzl A; Rammensee HG; Klingel K; Stevanović S
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4163-70. PubMed ID: 16857787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of MHC class II restricted T-cell-mediated reactivity against MHC class I binding Mycobacterium tuberculosis peptides.
    Wang M; Tang ST; Stryhn A; Justesen S; Larsen MV; Dziegiel MH; Lewinsohn DM; Buus S; Lund O; Claesson MH
    Immunology; 2011 Apr; 132(4):482-91. PubMed ID: 21294723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unbiased Characterization of Peptide-HLA Class II Interactions Based on Large-Scale Peptide Microarrays; Assessment of the Impact on HLA Class II Ligand and Epitope Prediction.
    Wendorff M; Garcia Alvarez HM; Østerbye T; ElAbd H; Rosati E; Degenhardt F; Buus S; Franke A; Nielsen M
    Front Immunol; 2020; 11():1705. PubMed ID: 32903714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular localization and polymorphism of HLA class II restriction determinants defined by Mycobacterium leprae-reactive helper T cell clones from leprosy patients.
    Ottenhoff TH; Neuteboom S; Elferink DG; de Vries RR
    J Exp Med; 1986 Dec; 164(6):1923-39. PubMed ID: 2431092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.